The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Open accessAbstract
Objective: To examine interactions of apolipoprotein E ( APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging. Methods: Two hundred forty‐one cognitively normal individuals, aged 45–88 years, had cerebral amyloid imaging studies with Pittsburgh Compound‐B (PIB). Of the 241 individuals, 168 (70%) also had cerebrospinal fluid (CSF) assays of amyloid‐beta 42 (Aβ 42 ), tau, and phosphorylated tau (ptau 181 ). All individuals were genotyped for APOE . Results: The frequency of individuals with elevated mean cortical binding potential (MCBP) for PIB rose in an age‐dependent manner from 0% at ages 45–49 years to 30.3% at 80–88 years. Reduced levels of CSF Aβ 42 appeared to begin earlier (18.2% of those aged 45–49 years) and increase with age in higher frequencies (50% at age 80–88 years) than elevations of MCBP. There was a gene dose effect for the APOE4 genotype, with greater MCBP increases and greater reductions in CSF Aβ 42 with increased numbers of APOE4 alleles. Individuals with an APOE2 allele had no increase in MCBP with age and had higher CSF Aβ 42 levels than individuals without an APOE2 allele. There was no APOE4 or APOE2 effect on CSF tau or ptau 181 . Interpretation: Increasing cerebral Aβ deposition with age is the pathobiological phenotype of APOE4 . The biomarker sequence that detects Aβ deposition may first be lowered CSF Aβ 42 , followed by elevated MCBP for PIB. A substantial proportion of cognitively normal individuals have presumptive preclinical AD. ANN NEUROL 2010;67:122–131
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE status has been found to modulate the onset of extracellular amyloid plaque deposition, one of the key pathognomonic features of the disease (6, 7).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous cross-sectional studies indicate that Aβ42 levels decrease in the CSF as Aβ starts to accumulate, before fibrillar plaques can be detected with PET7–11.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“On the basis of previous studies (7, 27), individuals with mean cortical binding potential (MCBP) for PIB >0.18 were considered PIB-positive (PIB+).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Increasing age and ApoE genetic background are the strongest known risk factors for AD and plaque load (33, 48); thus it was critical that these parameters were controlled.”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Sex differences in Aβ burden alone have not been reported in older adults,11–13”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,345
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Cited by
Sorted by citations
Items 201–300 of 835
Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia
Nadkarni, N. K., Perera, S., Snitz, B. E., Mathis, C. A., Price, J. C., Williamson, J. D., DeKosky, S. T., Klunk, W. E., & López, O. L. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3474 · Cited by 94
Kandel, B. M., Avants, B., Gee, J. C., McMillan, C. T., Erus, G., Doshi, J. J., Davatzikos, C. A., Wolk, D. A., & Initiative, A. D. N. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.03.001 · Cited by 98
Hippocampal atrophy rates and CSF biomarkers in elderly APOE 2 normal subjects
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., Jack, C. R., Aisen, P. S., Petersen, R. C., Weiner, M. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4d1 · Cited by 94
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease
Le Guen, Y., Belloy, M. E., Grenier-Boley, B., de Rojas, I., Castillo-Morales, A., Jansen, I., Nicolas, A., Bellenguez, C., Dalmasso, C., Küçükali, F., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1166 · Cited by 93
Long-term prognosis and educational determinants of brain network decline in older adult individuals
Chan, M. Y., Han, L., Carreno, C. A., Zhang, Z., Rodriguez-Boerwinkle, R. M., LaRose, M., Hassenstab, J. J., & Wig, G. S. (2021) · Nature Aging · doi:10.1038/s43587-021-00125-4 · Cited by 102
The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86
“…presence of an APOE ε 4 allele and lower levels of education increase the likelihood and rate of developing symptoms of ADem, but the presence of APOE ε 4 was shown to be the dominant factor (it is worth noting that studies have shown that APOE ε 4 is linked to CSF A β 1 – 42 accumulation [8, 53]).”
Individual estimates of age at detectable amyloid onset for risk factor assessment
Bilgel, M., An, Y., Zhou, Y., Wong, D. F., Prince, J. L., Ferrucci, L., & Resnick, S. M. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.166 · Cited by 94
Cheng, X. R., Hau, B. Y. H., Endo, T., & Kerman, K. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.10.003 · Cited by 90
Hu, W. T., Chen‐Plotkin, A. S., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M. J., McCluskey, L. F., Elman, L. B., Karlawish, J. H., Hurtig, H. I., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0723-9 · Cited by 90
Signs and Artifacts in Amyloid PET
Lundeen, T. F., Seibyl, J. P., Covington, M. F., Eshghi, N., & Kuo, P. H. (2018) · Radiographics · doi:10.1148/rg.2018180160 · Cited by 91
The role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019) · Neuronal Signaling · doi:10.1042/ns20180203 · Cited by 94
Buckley, R. F., Mormino, E. C., Chhatwal, J. P., Schultz, A. P., Rabin, J. S., Rentz, D. M., Acar, D., Properzi, M. J., Dumurgier, J., Jacobs, H. I. L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.019 · Cited by 89
APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases
Shvetcov, A., Johnson, E. C. B., Winchester, L. M., Walker, K. A., Wilkins, H. M., Thompson, T. G., Rothstein, J. D., Krish, V., Imam, F. B., The Global Neurodegeneration Proteomics Consortium (GNPC), et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03835-z · Cited by 78
Cerebrospinal Fluid Aβ42, Phosphorylated Tau181, and Resting-State Functional Connectivity
Wang, L. Y., Brier, M. R., Snyder, A. Z., Thomas, J., Fagan, A. M., Xiong, C., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., & Ances, B. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3253 · Cited by 90
Self-citationWierenga, C. E., Dev, S. I., Shin, D. D., Clark, L. R., Bangen, K. J., Jak, A. J., Rissman, R. A., Liu, T. T., Salmon, D. P., & Bondi, M. W. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.58 · Cited by 89
Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88
Self-citationDementia in late-onset epilepsy
Johnson, E. L., Krauss, G. L., Kucharska‐Newton, A., Albert, M., Brandt, J., Walker, K. A., Yaşar, S., Knopman, D. S., Vossel, K. A., & Gottesman, R. F. (2020) · Neurology · doi:10.1212/wnl.0000000000011080 · Cited by 89
Cairns, N. J., Perrin, R. J., Franklin, E. E., Carter, D., Vincent, B., Xie, M., Bateman, R. J., Benzinger, T., Friedrichsen, K., Brooks, W. S., et al. (2015) · Neuropathology · doi:10.1111/neup.12205 · Cited by 86
Self-citationLaws, S. M., Gaskin, S., Woodfield, A., Srikanth, V. K., Bruce, D. G., Fraser, P. E., Porter, T., Newsholme, P., Wijesekara, N., Burnham, S. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09577-4 · Cited by 98
Ikonomović, M. D., Abrahamson, E. E., Price, J. C., Hamilton, R. L., Mathis, C. A., Paljug, W. R., Debnath, M. L., Cohen, A. D., Mizukami, K., DeKosky, S. T., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0943-2 · Cited by 87
Selective Disruption of the Cerebral Neocortex in Alzheimer's Disease
Desikan, R. S., Sabuncu, M. R., Schmansky, N. J., Reuter, M., Cabral, H., Hess, C. P., Weiner, M. W., Biffi, A., Anderson, C. D., Rosand, J. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012853 · Cited by 83
van Rossum, I. A., Visser, P. J., Knol, D. L., van der Flier, W. M., Teunissen, C. E., Barkhof, F., Blankenstein, M. A., & Scheltens, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111694 · Cited by 84
Pietrzak, R. H., Lim, Y. Y., Ames, D. J., Harrington, K., Restrepo, C., Martins, R. N., Rembach, A., Laws, S. M., Masters, C. L., Villemagne, V. L., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.015 · Cited by 88
Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N. (2011) · Human Brain Mapping · doi:10.1002/hbm.21386 · Cited by 85
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
Ma, L., Tan, L., Bi, Y., Shen, X., Xu, W., Ma, Y., Li, H., Dong, Q., & Yu, J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00374-8 · Cited by 89
Longitudinal Changes of CSF Biomarkers in Alzheimer's Disease
Seppälä, T. T., Koivisto, A. M., Hartikainen, P. H., Helisalmi, S., Soininen, H. S., & Herukka, S. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101911 · Cited by 83
Soldan, A., Pettigrew, C. A., Li, S., Wang, M., Moghekar, A., Selnes, O. A., Albert, M., & O’Brien, R. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.017 · Cited by 89
Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD
Wolk, D. A., Mancuso, L., Kliot, D., Arnold, S. E., & Dickerson, B. C. (2013) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2013.02.014 · Cited by 84
Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan
Fouquet, M., Besson, F. L., Gonneaud, J., Joie, R. L., & Chételat, G. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9263-8 · Cited by 89
Obesity Accelerates Alzheimer-Related Pathology inAPOE4but notAPOE3Mice
Moser, V. A., & Pike, C. J. (2017) · eNeuro · doi:10.1523/eneuro.0077-17.2017 · Cited by 85
Origins of Alzheimerʼs disease
Musiek, E. S., & Holtzman, D. M. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a30f4 · Cited by 85
Self-citationGray matter network associated with risk for Alzheimer's disease in young to middle-aged adults
Alexander, G. E., Bergfield, K. L., Chen, K., Reiman, E. M., Hanson, K. D., Lin, L., Bandy, D. J., Caselli, R. J., & Moeller, J. R. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.014 · Cited by 91
Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies
Goldberg, T. E., Huey, E. D., & Devanand, D. P. (2020) · Nature Communications · doi:10.1038/s41467-020-18198-x · Cited by 82
Johnstone, D. M., Milward, E. A., Berretta, R. E., Moscato, P., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034341 · Cited by 83
Gray matter maturation and cognition in children with different APOE ε genotypes
Chang, L., Douet, V., Bloss, C. S., Lee, K., Pritchett, A., Jernigan, T. L., Akshoomoff, N. A., Murray, S. S., Frazier, J. A., Kennedy, D. N., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002939 · Cited by 81
Cigarette smoke and related risk factors in neurological disorders: An update
Smilin Bell Aseervatham, G., Choi, S., Krishnan, J., & Kandasamy, R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.118 · Cited by 83
Clusterin levels are increased in A lzheimer's disease and influence the regional distribution of Aβ
Miners, J. S., Clarke, P., & Love, S. (2016) · Brain Pathology · doi:10.1111/bpa.12392 · Cited by 83
Mosconi, L., Walters, M., Sterling, J. L., Quinn, C. G., McHugh, P. F., Andrews, R. D., Matthews, D. C., Ganzer, C. A., Osorio, R. S., Isaacson, R., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019362 · Cited by 86
Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease
Lim, Y. Y., Maruff, P. T., Pietrzak, R. H., Ellis, K. A., Darby, D., Ames, D. J., Harrington, K., Martins, R. N., Masters, C. L., Szoeke, C. E. I., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.11.005 · Cited by 84
An overview of the genes and biomarkers in Alzheimer’s disease
Krishnamurthy, H. K., Jayaraman, V., Krishna, K., Wang, T., Bei, K., Changalath, C., & Rajasekaran, J. J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102599 · Cited by 89
Jo, T., Nho, K., Bice, P., Saykin, A. J., & Initiative, F. T. A. D. N. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac022 · Cited by 80
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Milà‐Alomà, M., Suárez‐Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 81
Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease
Wang, L. Y., Benzinger, T. L. S., Hassenstab, J. J., Blazey, T., Owen, C., Liu, J., Fagan, A. M., Morris, J. C., & Ances, B. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001401 · Cited by 79
Self-citation11C-PiB Imaging of Human Immunodeficiency Virus–Associated Neurocognitive Disorder
Ances, B. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.761 · Cited by 78
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
Maternal family history is associated with Alzheimer's disease biomarkers
Honea, R. A., Initiative, F. T. A. D. N., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120676 · Cited by 79
Liao, F., Zhang, T. J., Jiang, H., Lefton, K. B., Robinson, G. O., Vassar, R., Sullivan, P. M., & Holtzman, D. M. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0250-y · Cited by 77
Self-citationPreclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept
Epelbaum, S., Genthon, R., Cavedo, E., Habert, M. O., Lamari, F., Gagliardi, G. P., Lista, S., Teichmann, M., Bakardjian, H., Hampel, H. J., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.003 · Cited by 82
Bejanin, A., Iulita, M. F., Vilaplana, E., Carmona-Iragui, M., Benejam, B., Videla, L., Barroeta, I., Fernandez, S., Altuna, M., Pegueroles, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1893 · Cited by 76
Role of HIV in Amyloid Metabolism
Ortega, M., & Ances, B. M. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9546-0 · Cited by 78
Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Antelmi, L., Bagnoli, C., David Bartrés-faz, A., Cordone, S., Didic, M., Farotti, L., et al. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12482 · Cited by 76
Disentangling the effects of age and APOE on neuropathology and late life cognitive decline
Yu, L., Boyle, P. A., Leurgans, S., Schneider, J. A., & Bennett, D. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.074 · Cited by 71
Chiotis, K., Saint‐Aubert, L., Boccardi, M., Gietl, A. F., Picco, A., Varrone, A., Garibotto, V., Herholz, K., Nobili, F. M., Nordberg, A. K., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.012 · Cited by 75
Detecting At-Risk Alzheimer’s Disease Cases
Fladby, T., Pålhaugen, L., Selnes, P., Waterloo, K. K., Bråthen, G., Hessen, E., Almdahl, I. S., Arntzen, K. A., Auning, E., Eliassen, C. F., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170231 · Cited by 77
Shi, L., Westwood, S., Baird, A. L., Winchester, L. M., Dobričić, V., Kilpert, F., Hong, S., Franke, A., Hye, A., Ashton, N. J., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4951 · Cited by 70
Genetic variation in APOE cluster region and Alzheimer's disease risk
Cervantes, S., Samaranch, L., Vidal-Taboada, J. M., Lamet, I., Bullido, M. J., Frank-García, A., Coria, F., Lleó, A., Clarimón, J., Lorenzo, E., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.023 · Cited by 62
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
Fu, Y., Zhao, J., Atagi, Y., Nielsen, H. M., Liu, C.-C., Zheng, H., Shinohara, M., Kanekiyo, T., & Bu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0099-y · Cited by 69
Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly
Malek-Ahmadi, M., Perez, S. E., Chen, K., & Mufson, E. J. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160365 · Cited by 73
Kantarci, K., Lowe, V. J., Przybelski, S. A., Senjem, M. L., Weigand, S. D., Ivnik, R. J., Roberts, R. O., Geda, Y. E., Boeve, B. F., Knopman, D. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822dc7e1 · Cited by 73
Proteome-Based Plasma Markers of Brain Amyloid-β Deposition in Non-Demented Older Individuals
Thambisetty, M., Tripaldi, R., Riddoch‐Contreras, J., Hye, A., An, Y., Campbell, J., Sojkova, J., Kinsey, A. M., Lynham, S., Zhou, Y., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101350 · Cited by 72
The neuropsychology of normal aging and preclinical Alzheimer's disease
Caselli, R. J., Locke, D. E. C., Dueck, A. C., Knopman, D. S., Woodruff, B. K., Hoffman‐Snyder, C., Rademakers, R., Fleisher, A., & Reiman, E. M. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.004 · Cited by 73
Shi, J., Leporé, N., Gutman, B. A., Thompson, P. M., Baxter, L. C., Caselli, R. J., Wang, Y., & Initiative, A. D. N. (2014) · Human Brain Mapping · doi:10.1002/hbm.22447 · Cited by 74
Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
Holland, D., McEvoy, L. K., Desikan, R. S., Dale, A. M., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047739 · Cited by 71
Shinohara, M., Petersen, R. C., Dickson, D. W., & Bu, G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1086-9 · Cited by 56
(ADNI), F. T. A. D. N. I., Yan, Q., Nho, K., Del-Aguila, J. L., Wang, X., Risacher, S. L., Fan, K.-H., Snitz, B. E., Aizenstein, H. J., Mathis, C. A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-018-0246-7 · Cited by 73
Leuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 73
Lack of association between prior depressive episodes and cerebral [11C]PiB binding
Madsen, K., Hasselbalch, B. J., Frederiksen, K. S., Haahr, M. E., Gade, A., Law, I., Price, J. C., Knudsen, G. M., Kessing, L. V., & Hasselbalch, S. G. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.021 · Cited by 66
The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68
Self-citationMosconi, L., Rinne, J. O., Tsui, W. H., Murray, J., Li, Y., Glodzik, L., McHugh, P. F., Williams, S., Cummings, M., Pirraglia, E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.002 · Cited by 69
Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J. S., Cho, M., & Hampel, H. J. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01669-5 · Cited by 70
Self-citationAshford, J. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150381 · Cited by 66
Imaging Biomarkers Associated With Cognitive Decline: A Review
McConathy, J., & Sheline, Y. I. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.08.024 · Cited by 68
A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimer’s Disease
Roe, C. M., Stout, S. H., Rajasekar, G., Ances, B. M., Jones, J. M., Head, D. M., Benzinger, T. L. S., Williams, M., Davis, J. D., Ott, B. R., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181242 · Cited by 65
Self-citationDistinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease
Kljajević, V., Grothe, M. J., Ewers, M., & Teipel, S. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.006 · Cited by 67
Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts
Resnick, S. M., Bilgel, M., Moghekar, A., An, Y., Cai, Q., Wang, M., Thambisetty, M., Prince, J. L., Zhou, Y., Soldan, A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.001 · Cited by 65
Johnston, J. M., Hu, W. T., Fardo, D. W., Greco, S. J., Perry, G. L., Montine, T. J., Trojanowski, J. Q., Shaw, L. M. J., Ashford, J. W., & Tezapsidis, N. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212114156 · Cited by 64
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 68
Transcriptional Effects of ApoE4: Relevance to Alzheimer’s Disease
Theendakara, V., Peters-Libeu, C. A., Bredesen, D. E., & Rao, R. V. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0757-2 · Cited by 63
Pettigrew, C. A., Soldan, A., Li, S., Lu, Y., Wang, M., Selnes, O. A., Moghekar, A., O’Brien, R., Albert, M., & Research Team the BIOCARD (2013) · Cognitive Neuroscience · doi:10.1080/17588928.2013.831820 · Cited by 63
Influence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study
Li, B., Shi, J., Gutman, B. A., Baxter, L. C., Thompson, P. M., Caselli, R. J., Wang, Y., & Initiative, A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152901 · Cited by 67
Shu, H., Shi, Y., Chen, G., Wang, Z., Liu, D., Yue, C., Ward, B. D., Li, W., Xu, Z., Chen, G., et al. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhu237 · Cited by 63
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 78
Relative effect of APOE ε4 on neuroimaging biomarker changes across the lifespan
Gonneaud, J., Arenaza‐Urquijo, E. M., Fouquet, M., Perrotin, A., Fradin, S., Sayette, V. D. L., Eustache, F., & Chételat, G. (2016) · Neurology · doi:10.1212/wnl.0000000000003234 · Cited by 65
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 64
APOE ε2ε4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults
Oveisgharan, S., Buchman, A. S., Yu, L., Farfel, J., Hachinski, V., Gaiteri, C., De Jager, P. L., Schneider, J. A., & Bennett, D. A. (2018) · Neurology · doi:10.1212/wnl.0000000000005677 · Cited by 62
Towards an understanding of women’s brain aging: the immunology of pregnancy and menopause
Barth, C., & de Lange, A. G. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100850 · Cited by 60
Sequence of Alzheimer disease biomarker changes in cognitively normal adults
Luo, J. R., Agboola, F., Grant, E., Masters, C. L., Albert, M., Johnson, S. C., McDade, E., Vöglein, J., Fagan, A. M., Benzinger, T. L. S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010747 · Cited by 59
Self-citationAmyloid imaging, Risk Disclosure and Alzheimer’s Disease: Ethical and Practical Issues
Roberts, J. S., Dunn, L. B., & Rabinovici, G. D. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.25 · Cited by 64
Wang, R., Fratiglioni, L., Kalpouzos, G., Lövdén, M., Laukka, E. J., Bronge, L. H., Wahlund, L., Bäckman, L., & Qiu, C. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.2363 · Cited by 61
Tisato, V., Zuliani, G., Vigliano, M., Longo, G., Franchini, E., Secchiero, P., Zauli, G., Paraboschi, E. M., Singh, A. V., Serino, M. L., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193867 · Cited by 61
Watson, C. M., Dammer, E. B., Ping, L., Duong, D. M., Modeste, E. S., Carter, E. K., Johnson, E. C. B., Levey, A. I., Lah, J. J., Roberts, B. R., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02158-3 · Cited by 59
Duara, R., Loewenstein, D., Shen, Q., Barker, W., Potter, E., Varón, D., Heurlin, K., Vandenberghe, R. R., & Buckley, C. J. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.006 · Cited by 60
Neuroimaging Measures as Endophenotypes in Alzheimer′s Disease
Braskie, M. N., Ringman, J. M., & Thompson, P. M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/490140 · Cited by 62
Zetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. J. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 63
Lehmann, M., Ghosh, P., Madison, C. A., Karydas, A., Coppola, G., O’Neil, J. P., Huang, Y., Miller, B. L., Jagust, W., & Rabinovici, G. D. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305858 · Cited by 61
Genetics of Alzheimer’s disease: From pathogenesis to clinical usage
Shao, W., Peng, D., & Wang, X. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.074 · Cited by 64
Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease
Ali, M., Archer, D. B., Gorijala, P., Western, D., Timsina, J., Fernández, M. V., Wang, T.-C., Satizabal, C. L., Yang, Q., Beiser, A. S., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01563-4 · Cited by 54
Self-citationShinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., Rakugi, H., & Morishita, R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00071 · Cited by 60
Metadata
- Authors
- Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Morris, John C.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 67
- Issue
- 1
- Pages
- 122-131
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2830375
- OpenAlex
- W2014897304
- Cited by
- 830
- References
- 80
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 38 · 2023: 39 · 2022: 54 · 2021: 40 · 2020: 53 · 2019: 53 · 2018: 49 · 2017: 58 · 2016: 54 · 2015: 48 · 2014: 65 · 2013: 76 · 2012: 63
- FWCI
- 32.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000448)
- National Institute on Aging (P50AG005681, P01AG003991, P01AG026276)
- National Center for Research Resources (UL1RR024992)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- apolipoprotein E, APOE ε4, APOE2, amyloid-beta, tau protein, preclinical Alzheimer's disease, Pittsburgh compound B, cerebrospinal fluid biomarkers, gene dosage effect, phosphorylated tau
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Aniline Compounds, Apolipoproteins E, Brain, Female, Follow-Up Studies, Genotype, Humans, Longitudinal Studies, Male, Middle Aged, Peptide Fragments, Phosphorylation, Thiazoles, Amyloid beta-Peptides, tau Proteins, Apolipoprotein E4, Apolipoprotein E2, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
